A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 614 participants.

Also called NCT02532855

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 614 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02532855
  • EudraCT 2014-005525-13
Other papers using this trial's data
  • A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study Diabetes, obesity & metabolism, 2018-12 DOI, PubMed 30019498, PMC6283039 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02532855. Randomized; triple masking; primary purpose treatment. Start 2015-10-20 (actual); primary completion 2017-10-10 (actual). Results posted on 2018-10-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Metformin
Intervention (Drug)
Matching placebo to sitagliptin
Intervention (Drug)
Matching placebo to dapagliflozin
Intervention (Drug)
Sulfonylurea
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct02532855
Content hash
170884358724e168e86b3c99e1114f601ec7ee085d930d42ddbcc450426fd935